# Investigation of Efficacy and Safety of Ragweed MATAMPL, Pollinex-R and Placebo in Patients With Ragweed Allergy

> **NCT00110786** · PHASE2 · COMPLETED · sponsor: **Allergy Therapeutics** · enrollment: 240 (—)

## Conditions studied

- Type I Hypersensitivity

## Interventions

- **BIOLOGICAL:** Ragweed MATAMPL

## Key facts

- **NCT ID:** NCT00110786
- **Lead sponsor:** Allergy Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** —
- **Final completion:** 2005-12
- **Target enrollment:** 240 (—)
- **Last updated:** 2010-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00110786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00110786, "Investigation of Efficacy and Safety of Ragweed MATAMPL, Pollinex-R and Placebo in Patients With Ragweed Allergy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00110786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*